MEMORANDUM FOR SGVT
ATTN: MAJ KELVIN N BUSH

FROM: 59 MDW/SGVU

SUBJECT: Professional Presentation Approval

1. Your paper, entitled A Case of Chagas Cardiomyopathy Following Infection in South Central Texas presented at/published to Oral Presentation: 2017 James Steele Conference on Diseases in Nature Transmissible to Man, Irving, TX, 24-26 May 2017 in accordance with MDW 41-108, has been approved and assigned local file #17166.

2. Pertinent biographic information (name of author(s), title, etc.) has been entered into our computer file. Please advise us (by phone or mail) that your presentation was given. At that time, we will need the date (month, day and year) along with the location of your presentation. It is important to update this information so that we can provide quality support for you, your department, and the Medical Center commander. This information is used to document the scholarly activities of our professional staff and students, which is an essential component of Wilford Hall Ambulatory Surgical Center (WHASC) internship and residency programs.

3. Please know that if you are a Graduate Health Sciences Education student and your department has told you they cannot fund your publication, the 59th Clinical Research Division may pay for your basic journal publishing charges (to include costs for tables and black and white photos). We cannot pay for reprints. If you are a 59 MDW staff member, we can forward your request for funds to the designated Wing POC at the Chief Scientist’s Office, Ms. Alice Houy, office phone: 210-292-8029; email address: alice.houy.civ@mail.mil.

4. Congratulations, and thank you for your efforts and time. Your contributions are vital to the medical mission. We look forward to assisting you in your future publication/presentation efforts.

LINDA STEEL-GOODWIN, Col, USAF, BSC
Director, Clinical Investigations & Research Support

Warrior Medics — Mission Ready — Patient Focused
1. The author must complete page two of this form:
   a. In Section 2, add the funding source for your study (e.g., 59 MDW CRD Graduate Health Sciences Education (GHSE) (SG5 O&M); SG5 R&D; Tri-Service Nursing Research Program (TSNRP); Defense Medical Research & Development Program (DMRDP); NIH; Congressionally Directed Medical Research Program (CDMRP); Grants; etc.)
   b. In Section 2, there may be funding available for journal costs, if your department is not paying for figures, tables or photographs for your publication. Please state "YES" or "NO" in Section 2 of the form, if you need publication funding support.

2. Print your name, rank/rate, sign and date the form in the author’s signature block or use an electronic signature.

3. Attach a copy of the 59 MDW IRB or IACUC approval letter for the research related study. If this is a technical publication/presentation, state the type (e.g. case report, QA/QI study, program evaluation study, informational report/briefing, etc.) in the "Protocol Title" box.

4. Attach a copy of your abstract, paper, poster and other supporting documentation.

5. Save and forward, via email, the processing form and all supporting documentation to your unit commander, program director or immediate supervisor for review/approval.

6. On page 2, have either your unit commander, program director or immediate supervisor:
   a. Print their name, rank/rate, title; sign and date the form in the approving authority’s signature block or use an electronic signature.

7. Submit your completed form and all supporting documentation to the CRD for processing (59crdpubsbrs@us.af.mil). This should be accomplished no later than 30 days before final clearance is required to publish/present your materials. If you have any questions or concerns, please contact the 59 CRD/Publications and Presentations Section at 292-7141 for assistance.

8. The 59 CRD/Publications and Presentations Section will route the request form to clinical investigations, 502 ISGUJAC (Ethics Review) and Public Affairs (59 MDW/PA) for review and then forward you a final letter of approval or disapproval.

9. Once your manuscript, poster or presentation has been approved for a one-time public release, you may proceed with your publication or presentation submission activities, as stated on this form. Note: For each new release of medical research or technical information as a presentation/publication, a new 59 MDW Form 3039 must be submitted for review and approval.

10. If your manuscript is accepted for scientific publication, please contact the 59 CRD/Publications and Presentations Section at 292-7141. This information is reported to the 59 MDW/CRC. All medical research or technical information/presentations must be reported to the Defense Technical Information Center (DTIC). See 59 MDW 41-108, Presentation and Publication of Medical and Technical Papers, for additional information.

11. The Joint Ethics Regulation (JER) DoD 5500.07-R. Standards of Conduct, provides standards of ethical conduct for all DoD personnel and their interactions with other non-DoD entities, organizations, societies, conferences, etc. Part of the Form 3039 review and approval process includes a legal ethics review to address any potential conflicts related to DoD personnel participating in non-DoD sponsored conferences, professional meetings, publication/presentation disclosures to domestic and foreign audiences. DoD personnel accepting non-DoD contributions, awards, honoraria, gifts, etc. The specific circumstances for your presentation will determine whether a legal review is necessary. If you (as the author) or your supervisor check "NO" in block 17 of the Form 3039, your research or technical documents will not be forwarded to the 502 ISGUJAC legal office for an ethics review. To assist you in making this decision about whether to request a legal review, the following examples are provided as a guideline:

   For presentations before professional societies and organizations, the 59 MDW Public Affairs Office (PAO) will provide the needed review to ensure proper disclaimers are included and the subject matter of the presentation does not create any cause for DoD concern.

   If the sponsor of a conference or meeting is a DoD entity, an ethics review of your presentation is not required, since the DoD entity is responsible to obtain all approvals for the event.

   If the sponsor of a conference or meeting is a non-DoD commercial entity or an entity seeking to do business with the government, then your presentation should have an ethics review.

   If your travel is being paid for (in whole or in part) by a non-Federal entity (someone other than the government), a legal ethics review is needed. These requests for legal review should come through the 59 MDW Gifts and Grants Office to 502 ISGUJAC.

   If you are receiving an honorarium or payment for speaking, a legal ethics review is required.

   If you (as the author) or your supervisor check "YES" in block 17 of the Form 3039, your research or technical documents will be forwarded simultaneously to the 502 ISGUJAC legal office and PAO for review to help reduce turn-around time. If you have any questions regarding legal reviews, please contact the legal office at (210) 671-5765/3365, DSN 473.

NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement:

   "The views expressed are those of the [author(s)],[presenter(s)] and do not reflect the official views or policy of the Department of Defense or its Components"  

NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement for research involving humans:

   "The voluntary, fully informed consent of the subjects used in this research was obtained as required by 32 CFR 219 and DODI 3216.02_AF.40-402."  

NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement for research involving animals, as required by AFMAN 40-401 IP:

   "The experiments reported herein were conducted according to the principles set forth in the National Institute of Health Publication No. 80-23, Guide for the Care and Use of Laboratory Animals and the Animal Welfare Act of 1966, as amended."
**A Case of Chagas Cardiomyopathy Following Infection in South Central Texas**

---

**Authorship and Co-Author(s)**: List in the order they will appear in the manuscript.

<table>
<thead>
<tr>
<th>Last Name, First Name and M.I.</th>
<th>Grade/Rank</th>
<th>Squadron/Group/Office Symbol</th>
<th>Institution (If not 59 MDW)</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Primary/Corresponding Author</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kevin N. V. Bush, MD</td>
<td>O-4/Maj</td>
<td>959 CSPS/59MDW/SGVT</td>
<td>SAMMC</td>
</tr>
<tr>
<td>b. Bryant J. Webber MD</td>
<td>O-4/Maj</td>
<td>559 Trainee Health/59MDW/SGTT</td>
<td></td>
</tr>
<tr>
<td>c. Edward J. Wozniak, DVM, PhD, M.F.T</td>
<td>O-5/LtCol</td>
<td>Texas State Guard Medical Brigade HQ</td>
<td></td>
</tr>
<tr>
<td>d. David Chang, MD</td>
<td>O-3/Capt</td>
<td>959 CSPS/59MDW/SGVT</td>
<td>SAMMC</td>
</tr>
<tr>
<td>e. Matthew C. Wilson, DO</td>
<td>O-4/Maj</td>
<td>559 Trainee Health/59MDW/SGTT</td>
<td></td>
</tr>
</tbody>
</table>

---

I certify any human or animal research related studies were approved and performed in strict accordance with 32 CFR 219, AFMAN 40-401 IP, and 59 MDW 41-108. I have read the final version of the attached material and certify that it is an accurate manuscript for publication and/or presentation.

---

I certify any human or animal research related studies were approved and performed in strict accordance with 32 CFR 219, AFMAN 40-401 IP, and 59 MDW 41-108. I have read the final version of the attached material and certify that it is an accurate manuscript for publication and/or presentation.

---

I certify any human or animal research related studies were approved and performed in strict accordance with 32 CFR 219, AFMAN 40-401 IP, and 59 MDW 41-108. I have read the final version of the attached material and certify that it is an accurate manuscript for publication and/or presentation.

---

I certify any human or animal research related studies were approved and performed in strict accordance with 32 CFR 219, AFMAN 40-401 IP, and 59 MDW 41-108. I have read the final version of the attached material and certify that it is an accurate manuscript for publication and/or presentation.

---

I certify any human or animal research related studies were approved and performed in strict accordance with 32 CFR 219, AFMAN 40-401 IP, and 59 MDW 41-108. I have read the final version of the attached material and certify that it is an accurate manuscript for publication and/or presentation.

---

I certify any human or animal research related studies were approved and performed in strict accordance with 32 CFR 219, AFMAN 40-401 IP, and 59 MDW 41-108. I have read the final version of the attached material and certify that it is an accurate manuscript for publication and/or presentation.

---

I certify any human or animal research related studies were approved and performed in strict accordance with 32 CFR 219, AFMAN 40-401 IP, and 59 MDW 41-108. I have read the final version of the attached material and certify that it is an accurate manuscript for publication and/or presentation.
Abstract previously approved by BAMC PAO. Appropriate disclaimers included.
A Case of Chagas Cardiomyopathy Following Infection in South Central Texas

Kelvin N.V. Bush, MD; Bryant J. Webber, MD; Edward J. Wozniak DVM, PhD, MPH; David Chang, MD; Matthew C. Wilson, DO; James A. Watts, MD; Heather C. Yun, MD
San Antonio Military Medical Center, San Antonio, TX
Kelvin.n.bush.mil@mail.mil

Chagas disease has been identified by the World Health Organization as one of the most marginalized tropical zoonotic diseases despite affecting 8 million people worldwide. The *Trypanosoma cruzi* parasite and several genera and species of triatomine insect vectors (also called “kissing bugs”) have been well established to be the infectious origins for human Chagas disease throughout the New World Tropics and parts of the southern United States. To date, the vast majority of documented U.S. infections have been in Latin American immigrants who were infected in their home countries and it has been estimated that 300,000 infected immigrants presently reside in the United States. At present, there have been less than 30 autochthonous cases reported in the United States although since it was made reportable in Texas in 2013, the case count continues to climb and this low number is likely attributable to under recognition and reporting. We present a well-documented autochthonous case of Chagasic cardiomyopathy in an 18 year-old U.S. Air Force trainee, native Texan, who had positive screening for *T. cruzi* without any history of travel outside of the United States. We offer review of our extensive cardiovascular evaluation that was completed in order to diagnose, offer treatment options, and execute military relevant implications with effort to increase awareness of this under recognized and under reported condition.

The view(s) expressed herein are those of the author(s) and do not reflect the official policy or position of Brooke Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Air Force, the Department of the Army or the Department of Defense or the U.S. Government.

The views expressed are those of the author(s)/presenter(s) and do not reflect the official views or policy of the Department of Defense or its Components.